Literature DB >> 28812596

Targeted therapies: SOLO2 confirms olaparib maintenance in ovarian cancer.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28812596     DOI： 10.1038/nrclinonc.2017.130

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Authors:  Eric Pujade-Lauraine; Jonathan A Ledermann; Frédéric Selle; Val Gebski; Richard T Penson; Amit M Oza; Jacob Korach; Tomasz Huzarski; Andrés Poveda; Sandro Pignata; Michael Friedlander; Nicoletta Colombo; Philipp Harter; Keiichi Fujiwara; Isabelle Ray-Coquard; Susana Banerjee; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Patricia Pautier
Journal:  Lancet Oncol       Date:  2017-07-25       Impact factor: 41.316
  1 in total
  3 in total

1.  Engineered DNA Vaccination against Follicle-Stimulating Hormone Receptor Delays Ovarian Cancer Progression in Animal Models.

Authors:  Alfredo Perales-Puchalt; Krzysztof Wojtak; Elizabeth K Duperret; Xue Yang; Anna M Slager; Jian Yan; Kar Muthumani; Luis J Montaner; David B Weiner
Journal:  Mol Ther       Date:  2018-12-13       Impact factor: 11.454

2.  MiR-219-5p inhibits growth and metastasis of ovarian cancer cells by targeting HMGA2.

Authors:  Feng Xing; Zhijiao Song; Yuanying He
Journal:  Biol Res       Date:  2018-11-24       Impact factor: 5.612

3.  Identification of Key Genes and Pathway for Ovarian Neoplasms Using the OVDM1 Cell Line Based on Bioinformatics Analysis.

Authors:  Songna Yin; Juan Du; Jie Zhang; Xiang Zhang; Ke Ma
Journal:  Med Sci Monit       Date:  2019-06-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.